Search Articles

View query in Help articles search

Search Results (1 to 10 of 18 Results)

Download search results: CSV END BibTex RIS


Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial

Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial

Ando et al [3] reported that 89.6% of strains harbored MRMs, with 68.3% harboring par C mutations and 27% harboring gyr A mutations. Given the unavailability of resistance testing for MRMs and the high prevalence of strains harboring MRMs (89.6%), sitafloxacin is the preferred treatment for M genitalium infections at our facility. Ando et al [20] reported that sitafloxacin monotherapy cleared strains harboring wild-type par C and gyr A.

Naokatsu Ando, Daisuke Mizushima, Yosuke Shimizu, Yukari Uemura, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, Kenji Sadamasu, Takato Nakamoto, Takahiro Aoki, Koji Watanabe, Shinichi Oka, Hiroyuki Gatanaga

JMIR Res Protoc 2023;12:e52565